HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Higenbottam, T. Search for Related Content PubMed PubMed Citation Articles by Higenbottam, T.

Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease

A Case for Treatment

AstraZeneca R&D Charnwood, Loughborough, United Kingdom

Correspondence and requests for reprints should be addressed to Tim Higenbottam, M.D., D.Sc., Clinical Science, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH, UK. E-mail: tim.higenbottam{at}astrazeneca.com

Current pharmacotherapy for chronic obstructive pulmonary disease (COPD) relieves symptoms and reduces exacerbation through improving airflow limitation. Such drugs do not effectively improve exercise tolerance due in part to pulmonary hypertension associated with severe COPD, nor impact on its increased morbidity and mortality. Exercise intolerance is often improved (temporarily) by lung volume reduction surgery and pulmonary rehabilitation. Ambulatory oxygen is the most effective treatment of exercise limitation. Chronic cigarette smoking is the principal cause of COPD. An early change in smokers' lungs is pulmonary artery intimal thickening and vessel narrowing, which, as COPD develops, is correlated with both the severity of emphysema and bronchiolitis. This may be the consequence of combined smoking-induced apoptosis, inflammation, and imperfect repair. End-stage bronchiolitis and emphysema are likely to limit the effectiveness of bronchodilators and corticosteroids. There are effective treatments for idiopathic and scleroderma pulmonary arterial hypertension, which increase exercise tolerance and improve survival. Because idiopathic and COPD pulmonary hypertension share a common vascular intimal thickening, excess endothelin receptor expression, and plasma endothelin-1, an important therapeutic question to address is whether an oral endothelin-1 antagonist can improve exercise tolerance in severe COPD.

Key Words: apoptosis • endothelin-1 • exercise limitation • pulmonary hypertension • tobacco smoke

This article has been cited by other articles:

				V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1573 - 1619. [Full Text] [PDF]

				Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation, April 28, 2009; 119(16): 2250 - 2294. [Full Text] [PDF]

				D. Stolz and M. Tamm From the authors Eur. Respir. J., February 1, 2009; 33(2): 452 - 453. [Full Text] [PDF]

				D. Stolz, H. Rasch, A. Linka, M. Di Valentino, A. Meyer, M. Brutsche, and M. Tamm A randomised, controlled trial of bosentan in severe COPD Eur. Respir. J., September 1, 2008; 32(3): 619 - 628. [Abstract] [Full Text] [PDF]

				D. Stolz, M. Christ-Crain, N. G. Morgenthaler, D. Miedinger, J. Leuppi, C. Muller, R. Bingisser, J. Struck, B. Muller, and M. Tamm Plasma Pro-Adrenomedullin But Not Plasma Pro-Endothelin Predicts Survival in Exacerbations of COPD Chest, August 1, 2008; 134(2): 263 - 272. [Abstract] [Full Text] [PDF]

				M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Eur. Respir. J., July 1, 2008; 32(1): 198 - 209. [Abstract] [Full Text] [PDF]

				M. R. Fisher, G. J. Criner, A. P. Fishman, P. M. Hassoun, O. A. Minai, S. M. Scharf, a. H. E. Fessler, and for the National Emphysema Treatment Trial (NETT) Estimating pulmonary artery pressures by echocardiography in patients with emphysema Eur. Respir. J., November 1, 2007; 30(5): 914 - 921. [Abstract] [Full Text] [PDF]

				A. F. Shorr, J. L. Wainright, C. S. Cors, C. J. Lettieri, and S. D. Nathan Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant Eur. Respir. J., October 1, 2007; 30(4): 715 - 721. [Abstract] [Full Text] [PDF]

				L. M. Fabbri, F. Luppi, B. Beghe, and K. F. Rabe Update in chronic obstructive pulmonary disease 2005. Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1056 - 1065. [Full Text] [PDF]